Ikaria Holdings has announced that the FDA has granted orphan drug designation for inhaled carbon monoxide for use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplantation.

Ikaria Holdings, through its subsidiary Ino Therapeutics, has announced that Japan's Ministry of Health, Labor and Welfare has approved INOflo for inhalation for improvement of hypoxic respiratory failure with concurrent pulmonary hypertension in neonates.

Ikaria Holdings, a biotherapeutics company, has completed dosing of its Phase Ia trial for its drug candidate, IK-1001 for injection.

SEATTLE and CLINTON, N.J., Feb. 22 /PRNewswire/ -